Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
VERALOX Therapeutics logo — Pioneering therapies that address the root causes of thrombo...

VERALOX Therapeutics

Pioneering therapies that address the root causes of thrombosis and type one diabetes to improve patient outcomes.

Founded 2018 United States Frederick, United States 18 employees Venture round Total: $47.46M Biotechnology, Health and Wellness +1

General Information

Company Name VERALOX Therapeutics
Founded Year 2018
Location United States Frederick, United States
Founders / Decision Makers
Team member Team member
Employees 18
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with VERALOX Therapeutics . To contact VERALOX Therapeutics , visit veralox.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About VERALOX Therapeutics

VERALOX Therapeutics is a biotechnology startup founded in 2018 and based in the United States. The company is dedicated to accelerating the development of first-in-class therapeutics to address the root causes of thrombosis and type one diabetes, aiming to improve patient outcomes. With a focus on unmet medical needs, VERALOX Therapeutics has attracted significant attention from investors, most notably securing a $24.00M venture round investment on 20 June 2023. This funding round saw participation from influential organizations such as T1D Fund, Hatteras Venture Partners, Pappas Capital, Genesys Capital Management Inc, Sanofi Ventures, and NYBC Ventures. The company's pioneering approach and ambitious goals position it as a promising player in the biotechnology, health and wellness, and pharmaceutical industries.

Taxonomy: Thrombosis, Type One Diabetes, Small Molecule Treatments, Root Causes, Molecular Mechanisms, Therapeutic Approaches, Patient Outcomes, Pathologies, Treatment Paradigms, Medical Research, Drug Development, Healthcare Innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $24.00M 6
T1D Fund Hatteras Venture Partners Pappas Capital
T1D Fund, Hatteras Venture Partners +4
20 Jun 2023
Series A $16.60M 4
Hatteras Venture Partners TEDCO Point Field Partners
Hatteras Venture Partners, TEDCO +2
16 Jun 2021
Seed Round $5.40M -
05 Sep 2019
Debt Financing $1.46M -
22 May 2019

VERALOX Therapeutics Alternatives & Competitors

View All Alternatives
VERALOX Therapeutics vs
Genmedica Therapeutics
Genmedica Therapeutics

Pioneering the path towards disease-modifying solutions for type 2 diabetes

Venture round
11-50 employees
Biotechnology, Health Care
VERALOX Therapeutics vs
Pinteon Therapeutics
Pinteon Therapeutics

Pioneering therapies targeting Pin1 to normalize disease processes and enhance patient outcomes in c...

Series B
2-10 employees
Biotechnology, Health Care
VERALOX Therapeutics vs
Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited China

We are committed to developing the best therapeutics to improve human health.

Series D
29 employees
Biopharma, Biotechnology
View all alternatives

FAQ About VERALOX Therapeutics

Pioneering therapies that address the root causes of thrombosis and type one diabetes to improve patient outcomes.
VERALOX Therapeutics was founded in 2018.
VERALOX Therapeutics is headquartered in Frederick, United States.
VERALOX Therapeutics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Thrombosis, Type One Diabetes, Small Molecule Treatments and Root Causes.
VERALOX Therapeutics has approximately 18 employees.
VERALOX Therapeutics has completed 4 funding rounds, raising a total of $47.46M. The latest funding stage is Venture round.
Top alternatives and competitors to VERALOX Therapeutics include Genmedica Therapeutics, Pinteon Therapeutics, Kintor Pharmaceutical Limited, Asceneuron SA, Abarceo Pharma AB. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VERALOX Therapeutics and Genmedica Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VERALOX Therapeutics , https://bouncewatch.com/company/veralox-therapeutics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes